XOLAIR
Live / Registered — Registered and renewed (as of 12 Jan 2026)
What this means for you
Registered since 15 Mar 2016. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 15 Mar 2026).
Record
- Serial number
- 85829727
- Registration number
- 4918470
- Mark type
- Stylized text
- Filed
- 23 Jan 2013
- Published for opposition
- 04 Jun 2013
- Registered
- 15 Mar 2016
- Next maintenance due
- 15 Mar 2026
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of urticaria
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 12 Jan 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 12 Jan 2026 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 12 Jan 2026 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 12 Jan 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 07 Oct 2025 — TEAS SECTION 8 & 9 RECEIVED
- 15 Mar 2025 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 18 Jul 2022 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 18 Jul 2022 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 16 Jul 2022 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 08 Feb 2022 — TEAS SECTION 8 & 15 RECEIVED
- 15 Mar 2021 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 15 Mar 2016 — REGISTERED-PRINCIPAL REGISTER
- 06 Feb 2016 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Feb 2016 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 05 Feb 2016 — STATEMENT OF USE PROCESSING COMPLETE